人重组促红细胞生成素治疗脓毒症贫血的临床研究

目的 探讨人重组促红细胞生成素治疗脓毒症贫血的临床价值.方法 选择2005年6月至2006年12月天津医科大学第二医院ICU脓毒症伴有贫血患者60例,分为人重组促红细胞生成素治疗组(n=30)和对照组(n=30).所有患者均需排除肾功能不全需血液净化治疗者、消化道出血及曾经rhu-EPO治疗者.治疗组患者入院后48h起给予皮下注射人重组促红细胞生成素,每次6000U,隔日一次,连续两周;当Hb≤80 g/L,输红细胞治疗或根据病情由主诊医师决定.数据均以(-x±s)表示,计量资料用t检验,计数资料采用精确概率法检验,P＜0.05为差异具有统计学意义.结果 两组患者治疗前后血红蛋白比较,治疗前两组患者血红蛋白差异无统计学意义(P＞0.05).治疗后治疗组血红蛋白(105.87±11.48)g/L明显高于对照组(91.23±19.89)g/L(P＜0.01).治疗组输血量(2.0 ±0.47)U显著低于对照组(2.63±0.43)U(P＜0.01).两组患者死亡率差异无统计学意义(P＞0.05).结论 脓毒症合并贫血患者给予皮下注射人重组促红细胞生成素治疗可以显著提高血红蛋白水平,减少输血.

Clinical efficacy of recombinant human erythropoietin on sepsis with anemia

Objective To observe clinical efficacy of recombinant human erythropoietin(rhu-EPO)in sepsis with anemia.Method From June 2005 to December 2006,sixty sepsis with anemia patients in the Second Affiliated Hospital of Tianjin Medical University were divided into control group(n=30)and theatment with rhu-EPO group(n=30).The exclusion criteria was:renal imufficiency patients needing blood purification,patients with hemorrhage of digestive tract,and patients who used rhu-EPO before.Patients in the rhu-EPO group were hypodermically injected with rhu-EPO at 48 hours after admission,6000 units par time,and continued every other day for two weeks.When the hemoglobin Was lower than 80 g/L,patients received red blood cell(RBC)transfusion or received other treatment decided by doctor.The data were expressed as(x±s),and were analyzed using Student's t test and Fisher's exact test with SPSS 11.5.A P valLie less than 0.05 indicated statistical significance.Results There Was no significant difference on hemoglobin between the two groups before treatment (P＞0.05).After treatment,the hemoglobin of patients in rhu-EPO group was higher than that in control group [(105.87±11.48)g/L vs.(91.23 ±19.89)g/L,P＜0.01].The units of RBC transfusions was less in patients of rhu-EPO group compared with control group[(2.0 ±0.47)U vs.(2.63±0.43)U,P＜0.01].There was no significant difference on mortality between two groups(P＞0.05).Conclusions In sepsis with anemia patients,administration of rhu-EPO every other day can increase red blood cell level and reduce RBC transfusion.